Biopharma PEG Highlights the Critical Role of PEG-Lipid Nanoparticles in RNA Therapeutics

Watertown, MA, September 26, 2025 - In the past decade, lipid nanoparticles (LNPs) have emerged as the premier delivery vehicle for RNA-based medicines, powering the success of both siRNA drugs and mRNA vaccines. A key component of these systems is PEG-lipids, specialized polyethylene glycol (PEG) derivatives that stabilize nanoparticles, extend circulation time, and enhance safety.
Why PEG-Lipids Are Essential
RNA molecules are inherently unstable in the bloodstream, where they are rapidly degraded by enzymes and cleared by the kidneys. LNPs address this challenge, but without PEG-lipids, nanoparticles risk aggregation, rapid clearance, or immune activation. PEG-lipids provide multiple advantages:
Stabilization: Preventing nanoparticle aggregation during formulation, storage, and injection.
Extended Circulation: Creating a hydrophilic shield that reduces clearance by the immune system.
Controlled Delivery: Allowing fine-tuning of pharmacokinetics and biodistribution through PEG density and chain length.
Reduced Toxicity: Shielding surface charges to lower immune activation risks.
Onpattro: A Pioneering siRNA Success
The approval of Onpattro (patisiran) in 2018 marked the first FDA-approved siRNA therapeutic. Its delivery system featured DMG-PEG2000, a PEG-lipid critical to nanoparticle stability and performance. Once administered, PEG-lipids gradually detach, enabling efficient cellular uptake and endosomal escape. This milestone demonstrated that PEG-LNPs could make RNAi therapies safe and effective for patients.
COVID-19 Vaccines: PEG-LNPs at Global Scale
The development of the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines represented the largest-scale deployment of PEG-LNPs in history. Both vaccines rely on ionizable lipids, cholesterol, helper lipids, and PEG-lipids to protect and deliver fragile mRNA encoding the SARS-CoV-2 spike protein. PEG-lipids such as PEG2000-DMG are critical for maintaining stability during manufacturing and distribution while ensuring efficient delivery in vivo.
Biopharma PEG: Supplying the Building Blocks of RNA Medicine
As a global supplier, Biopharma PEG offers a broad range of high-purity PEG-lipids and derivatives to accelerate RNA drug development, including:
 PEG-lipids such as DMG-PEG2000, DSPE-PEG, and custom variants
Plant-derived cholesterol with high purity
GMP-grade PEGs available from milligram to 100 kg scale for clinical and commercial applications
"From pioneering siRNA therapies like Onpattro to life-saving COVID-19 vaccines, PEG-lipids have proven indispensable in advancing RNA therapeutics," said Sonia Lee, Head of Busniness Development at Biopharma PEG. "We are committed to providing the PEG solutions that enable the next generation of breakthroughs in oncology, infectious disease, and rare disorders."

Biopharma PEG Scientific Inc.
108 Water Street, Suite 4D, Watertown, MA 02472, USA
TEL: 1-857-928-2050 / 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com

Biopharma PEG is a leading global supplier of PEG derivatives and PEG-lipids for pharmaceutical R&D and commercial production. With expertise in custom synthesis, GMP production, and large-scale supply, Biopharma PEG supports the development of advanced drug delivery systems worldwide.

This release was published on openPR.